FOXP3⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF𝜶 Agents

Table 2

Immunohistochemical study: baseline characteristics of IBD patients and controls.

Variable	Results
	𝑁 (%)	Median (range)
IBD Patients	15 (100)
(i) Crohn’s disease	12 (80)
(ii) Ulcerative colitis	3 (20)
White race	15 (100)
Male	11 (73)
Age		33 (16–64)
Disease duration (months)		59 (13–264)
Medications at baseline
(i) Azathioprine	3 (20)
(ii) Steroids	4 (27)
(iii) Mesalamine	2 (13)
(iv) Steroids + immunosuppressors	2 (13)
(v) None	4 (27)
Anti-TNFα
(i) Infliximab	5 (33)
(ii) Infliximab + azathioprine	7 (47)
(iii) Certolizumab pegol + azathioprine	3 (20)
Histological sample location
(i) Colon	7 (47)
(ii) Ileum	8 (53)
Control patients (IBS)	8 (100)
Male	2 (25)
Age		38.5 (15–66)
Histological sample location
(i) Colon	0
(ii) Ileum	8 (100)

IBD: inflammatory bowel disease; TNF: tumor necrosis factor; IBS: irritable bowel syndrome.